title: [Infant botulism].
abstract: Infant botulism is a paralytic syndrome which manifests as a result of ingesting spores of the toxin secreting bacterium Clostridium botulinum by infants. As opposed to botulism in adults, treating infant botulism with horse antiserum was not approved due to several safety issues. This restriction has led to the development of Human Botulism Immune Globulin Intravenous (BIG-IV; sells under BabyBIG). In this article we review infant botulism and the advantages of treating it with BIG-IV.
authors.forename: Absalom
authors.initials: A
authors.lastname: Falk
authors.forename: Amichay
authors.initials: A
authors.lastname: Afriat
authors.forename: Yechiel
authors.initials: Y
authors.lastname: Hubary
authors.forename: Lior
authors.initials: L
authors.lastname: Herzog
authors.forename: Arik
authors.initials: A
authors.lastname: Eisenkraft
mesh_terms: D000367:Age Factors; D001906:Botulism / Q000188:drug therapy* / Q000382:microbiology / Q000503:physiopathology; D003014:Clostridium botulinum / Q000302:isolation & purification; D006801:Humans; D007136:Immunoglobulins / Q000627:therapeutic use*; D007155:Immunologic Factors / Q000627:therapeutic use*; D007223:Infant
chemical_list: D007136:Immunoglobulins; D007155:Immunologic Factors; C068584:botulism immune globulin